BridgeBio Pharma Inc. (NASDAQ: BBIO) announced it will present Phase 2 data for encaleret in post-surgical hypoparathyroidism at the American ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE